Yves Pommier

TL;DR: The rationale for developing TDP inhibitors for combinations with topoisomerase inhibitors, as well as the relevance of TDP1 and TDP2 as determinants of response to anticancer agents, are discussed.

TL;DR: The roles of γH2AX and PAR in the DDR, and their use as biomarkers to monitor drug response and guide clinical trials, especially phase 0 clinical trials are summarized.

TL;DR: Results of this trial reveal that PARP inhibition can modulate the capacity to repair topoisomerase I-mediated DNA damage in the clinic and show a mechanistic interaction of a PARP inhibitor, ABT-888, with a topoisomersase I inhibitor, topotecan, in PBMCs, tumor, and CTCs.

TL;DR: It is concluded that SLFN11 expression is causally associated with the activity ofDDAs in cancer cells, has a broad expression range in colon and ovarian adenocarcinomas, and may behave as a biomarker for prediction of response to DDAs in the clinical setting.

TL;DR: It is shown that the candidate second-generation drug dolutegravir (DTG, S/GSK1349572) effectively inhibits a panel of HIV-1 IN variants resistant to first-generation INSTIs and crystal structures suggest that DTG has the ability to subtly readjust its position and conformation in response to structural changes in the active sites of RAL-resistant INs.